UK MHRA approves Eli Lilly's (LLY) Iniuriyo for treatment of breast cancer

Eli Lilly's approval for Iniuriyo marks a significant advancement in their oncology portfolio, likely enhancing growth prospects and investor sentiment.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

US sells 6-week bills at high rate 3.635%; B/C 2.82x

European Closes: Euro Stoxx 50 +0.10% at 6,121, Dax 40 +0.12% at 25,022, FTSE 100 -0.04% at 10,681, CAC 40 +0.26% at 8,519, FTSE MIB -0.10% at 46,652, IBEX 35 -0.54% at 18,190, PSI +0.25% at 9,269, SMI +1.08% at 13,994, AEX +0.34% at 1,020

UK MHRA approves Eli Lilly's (LLY) Iniuriyo for treatment of breast cancer

NYT Opininon Piece says Trump's new tariffs are illegal too; notes "A Section 122 “payments problem” involves a flight from the U.S. dollar. At the moment, no such problem exists."

US posts notice of Trump order extending de minimis suspension

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Given the competitive landscape in pharmaceuticals, this could provide a strategic edge against peers, particularly if it captures market share in breast cancer treatment. Watch for potential reactions in Eli Lilly's stock and the broader biotech sector as expectations adjust to this news.

Related headlines

The whole workspace, free to try.

Try it free